Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438086 | 0.93 | MEN1 (0.39) | MEN1KMT2AFAAHMAPK1EPHX1 | |
| SCHEMBL13884348 | 0.91 | MEN1 (0.42) | MEN1KMT2AFAAHMAPK1EPHX1 | |
| SCHEMBL26700639 | 0.91 | MEN1 (0.42) | MEN1KMT2AFAAHMAPK1EPHX1 | |
| SCHEMBL20332107 | 0.91 | MEN1 (0.42) | MEN1KMT2AFAAHMAPK1EPHX1 | |
| SCHEMBL17446604 | 0.91 | MEN1 (0.42) | MEN1KMT2AFAAHMAPK1EPHX1 | |
| SCHEMBL25109878 | 0.91 | MEN1 (0.42) | MEN1KMT2AFAAHMAPK1EPHX1 | |
| SCHEMBL8797944 | 0.86 | BBOX1 (0.33) | MEN1KMT2AFAAHMAPK1ALDH1A1 | |
| SCHEMBL18592280 | 0.83 | KDM4E (0.37) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL25483567 | 0.83 | MEN1 (0.31) | MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL19654104 | 0.82 | CASP2 (0.44) | MEN1KMT2AFAAHMAPK1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023225650-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230372508-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | Singular Genomics Systems, Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11697736-B2 | Silicon containing detectable compounds | Singular Genomics Systems, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-06-03 | — | — | US | disclosed |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090247513-A1 | BENZOTHIOPHENE COMPOUNDS HAVING ANTIINFECTIVE ACTIVITY | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7589171-B2 | Polyamides for treating human papilloma virus | NANOVIR, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| US-7498405-B2 | Halogen-substituted thienyl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7329765-B2 | Benzothiophene compounds having antiinfective activity | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | NANOVIR, LLC | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | IRF3, BCL3, L3MBTL3 | MEN1 741/4885KMT2A 1133/4885FAAH 1796/4885 |
| US-11697736-B2 | Silicon containing detectable compounds | AS3MT, SCLY, NASP | MEN1 660/4885KMT2A 3136/4885FAAH 4634/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | MEN1 2268/4885KMT2A 1193/4885FAAH 2976/4885 |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | AS3MT, SCLY, NASP | MEN1 660/4885KMT2A 3136/4885FAAH 4634/4885 |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | TNFRSF1A, TNFRSF9, CD40 | MEN1 2811/4885KMT2A 4303/4885FAAH 3509/4885 |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | MEN1 2971/4885KMT2A 4193/4885FAAH 828/4885 |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | POLI, VHL, TLR3 | MEN1 2846/4885KMT2A 1119/4885FAAH 1361/4885 |
| US-20090247513-A1 | BENZOTHIOPHENE COMPOUNDS HAVING ANTIINFECTIVE ACTIVITY | TOP2A, TOP1, TOP2B | MEN1 4439/4885KMT2A 2444/4885FAAH 3627/4885 |
| US-20230372508-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | DNPEP, LNPEP, FGB | MEN1 2970/4885KMT2A 4010/4885FAAH 2821/4885 |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | MEN1 1517/4885KMT2A 310/4885FAAH 3355/4885 |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | POLI, PMAIP1, TLR3 | MEN1 2158/4885KMT2A 940/4885FAAH 2722/4885 |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | MEN1 2766/4885KMT2A 1237/4885FAAH 2957/4885 |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | POLI, PARG, PARN | MEN1 1624/4885KMT2A 193/4885FAAH 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.